Three execs resign as Dyne posts mixed data for DMD candidate

Three execs resign as Dyne posts mixed data for DMD candidate

Submitted by admin on September 3, 2024 - 5:56pm
Source: 
Fierce Biotech
News Tags: 
Dyne Therapeutics
DMD
DYNE-251
Headline: 
Three execs resign as Dyne posts mixed data for DMD candidate
snippet: 

After escaping a clinical hold several years back, Dyne Therapeutics has revealed new phase 1/2 data for its Duchenne muscular dystrophy (DMD) therapy DYNE-251. The readout notes several serious treatment-emergent adverse events (TEAEs), including acute kidney injury.

Do Not Allow Advertisers to Use My Personal information